Ito, Sadayoshi
Kashihara, Naoki
Shikata, Kenichi
Nangaku, Masaomi
Wada, Takashi
Okuda, Yasuyuki
Sawanobori, Tomoko
Funding for this research was provided by:
Daiichi Sankyo Company
Article History
Received: 28 February 2021
Accepted: 10 May 2021
First Online: 10 June 2021
Declarations
:
: Employment: Yasuyuki Okuda (Daiichi Sankyo Co., Ltd.) and Tomoko Sawanobori (Daiichi Sankyo Co., Ltd); Personal fees: Sadayoshi Ito (Daiichi Sankyo Co., Ltd.), Naoki Kashihara (Daiichi Sankyo Co., Ltd.), Kenichi Shikata (Daiichi Sankyo Co., Ltd.), Masaomi Nangaku (Daiichi Sankyo Co., Ltd.), and Takashi Wada (Daiichi Sankyo Co., Ltd); Grants/research funding received: Sadayoshi Ito (Daiichi Sankyo Co., Ltd.), Naoki Kashihara (Daiichi Sankyo Co., Ltd.), and Masaomi Nangaku (Daiichi Sankyo Co., Ltd).
: The study protocol was approved by the local institutional review board at each participating site and conducted in accordance with the principles outlined in the Declaration of Helsinki and ICH-E6-guideline for Good Clinical Practice (CPMP/ICH/135/95). All patients provided written informed consent prior to enrollment in the study.